Egrifta (Tesamorelin) Safety in Older Adults (50, 64)

Why Age 50 to 64 Requires a Separate Safety Discussion

Adults in this decade sit at a clinical crossroads. Baseline cardiovascular disease risk rises sharply after age 50, and people living with HIV who have survived into their sixth decade carry additional burden from chronic inflammation, antiretroviral exposure, and metabolic syndrome. Tesamorelin is the only FDA-approved treatment for HIV-associated lipodystrophy, making its risk-benefit calculus particularly relevant here.

The key Phase III trial by Falutz et al. (NEJM 2007) enrolled participants with a mean age in the early-to-mid 40s, and the subsequent registration trials (Study 1 and Study 2) included adults up to age 65 [1]. Subgroup analyses did not identify age as a significant modifier of efficacy or adverse-event rates. But these trials were not powered to detect age-stratified safety signals, and the proportion of participants over 50 was modest. The absence of a signal is not the same as confirmed safety. For the 50-to-64 cohort, a structured monitoring approach fills this evidence gap.

The Endocrine Society's clinical practice guidelines on GH-related peptides note that growth hormone axis activity declines roughly 14% per decade after age 30 [2]. Stimulating that axis in a 55-year-old produces a different physiological response than in a 35-year-old. The sections below walk through each domain of risk.

Cardiovascular Risk and Tesamorelin at Midlife

Tesamorelin reduces visceral adipose tissue (VAT), and VAT is an independent risk factor for cardiovascular events. On the surface, this suggests a cardiovascular benefit. The data partially support that interpretation.

In the pooled Phase III analysis (N=816), tesamorelin reduced trunk fat by 15.2% compared with a 5.0% increase in the placebo group over 26 weeks [1]. Triglycerides decreased by a mean of 50 mg/dL in treated patients, and total cholesterol-to-HDL ratio improved modestly [3]. These metabolic shifts are directionally favorable for a 55-year-old with dyslipidemia.

The concern sits on the other side of the ledger. Growth hormone releasing hormone (GHRH) analogs increase IGF-1, and sustained IGF-1 elevation above the age-adjusted upper limit of normal has been associated with increased risk of certain cancers and, in some epidemiologic datasets, with coronary artery disease [4]. The FDA prescribing information for Egrifta SV instructs clinicians to discontinue treatment if IGF-1 exceeds 3 SDS (standard deviation scores) above the mean for age and sex [5].

For patients aged 50 to 64, the clinical action step is clear: obtain a baseline lipid panel, fasting glucose, and HbA1c before starting tesamorelin. Repeat lipid assessment at 3 and 6 months. If triglycerides worsen despite VAT reduction, evaluate statin or fibrate interactions.

IGF-1 Monitoring: Age-Adjusted Reference Ranges Matter

This is where prescribers most commonly make errors in the older cohort. IGF-1 reference ranges decline with age. A value of 280 ng/mL might be mid-range for a 30-year-old but well above the 97.5th percentile for a 60-year-old.

In the Phase III trials, mean IGF-1 increased by approximately 81% from baseline with tesamorelin 2 mg daily [1]. Among participants over 50, the absolute post-treatment IGF-1 values were lower than in younger participants (reflecting lower baseline levels), but the relative increase was comparable. Three percent of all treated patients developed IGF-1 levels exceeding 3 SDS [5].

The National Institute on Aging has published reference data showing that mean IGF-1 falls from roughly 200 ng/mL at age 40 to 150 ng/mL at age 60 [6]. An 80% increase from a baseline of 150 ng/mL yields 270 ng/mL, which may exceed the age-matched 95th percentile but remain below the absolute threshold that would alarm a clinician accustomed to younger patients.

Recommended IGF-1 monitoring schedule for patients 50 to 64:

1. Draw baseline IGF-1 before first injection.
2. Recheck at 4 to 6 weeks after initiation.
3. If IGF-1 exceeds 2 SDS above age- and sex-matched mean, hold tesamorelin for 2 weeks and redraw.
4. If IGF-1 exceeds 3 SDS, discontinue per FDA labeling.
5. Annual surveillance thereafter if stable.

Always use the laboratory's age-adjusted reference intervals rather than a single absolute cutoff.

Polypharmacy: Drug Interactions in the 50-to-64 Window

Adults aged 50 to 64 living with HIV take a median of 6 concurrent medications according to data from the AGEhIV Cohort Study [7]. Tesamorelin does not pass through hepatic CYP450 metabolism to a clinically significant degree, but it does influence two axes that interact with commonly prescribed drugs.

Insulin and glucose metabolism. Tesamorelin can raise fasting glucose by 4 to 5 mg/dL and worsen insulin resistance in a subset of patients [5]. For a 58-year-old already on metformin for prediabetes, this means tighter glucose monitoring for the first 3 months. The American Diabetes Association Standards of Care recommend HbA1c rechecks at 3-month intervals when new medications alter glucose homeostasis [8].

Cortisol. Because tesamorelin acts through the GHRH receptor and GH stimulates cortisol clearance, patients on physiologic glucocorticoid replacement (for adrenal insufficiency or as part of certain HIV-related protocols) may need dose re-evaluation. This interaction is uncommon but clinically meaningful when it occurs.

Antiretroviral therapy (ART). No direct pharmacokinetic interactions have been documented between tesamorelin and NRTIs, NNRTIs, or integrase inhibitors [5]. Protease inhibitors (PIs) are themselves a contributor to lipodystrophy, and some older adults in this age group may still be on PI-based regimens. Tesamorelin can be used alongside PIs without dose modification, but the metabolic burden of combined GH-axis stimulation plus PI-induced insulin resistance warrants closer glucose surveillance.

Statins and fibrates. Tesamorelin's triglyceride-lowering effect can be additive with fibrates. While this is generally favorable, monitor for myopathy symptoms if a patient is on both a statin and a fibrate, as the margin of safety narrows with polypharmacy.

Injection-Site Reactions and Musculoskeletal Side Effects

The most frequently reported adverse events in tesamorelin trials were injection-site reactions (erythema, pruritus, pain) at 24.5% versus 14.4% in placebo, and arthralgia at 13.3% versus 8.5% in placebo [1][5]. These rates were not stratified by age in published subgroup analyses, but clinical experience suggests two age-relevant considerations.

First, skin at injection sites in adults over 50 tends to be thinner and less elastic. Rotating injection sites (abdomen only, per labeling) and using proper pinch technique may reduce local reactions. Patients should avoid injecting into areas of lipodystrophy-related induration.

Second, arthralgia from GH-axis stimulation may be harder to distinguish from age-related osteoarthritis in this cohort. Joint pain that begins within the first 4 weeks of tesamorelin and affects multiple joints symmetrically is more likely drug-related. Pain isolated to a single weight-bearing joint with morning stiffness exceeding 30 minutes is more likely degenerative. If drug-related arthralgia is intolerable, a 2-week drug holiday followed by rechallenge can help clarify the cause.

Peripheral edema, reported in 6.1% of treated patients [5], deserves attention in patients already managing fluid retention from calcium channel blockers or heart failure. Check lower extremity edema at each visit during the first 6 months.

Cancer Screening Before and During Therapy

The FDA label for Egrifta SV carries a precaution about malignancy. Tesamorelin is contraindicated in patients with active malignancy [5]. For adults aged 50 to 64, this intersects with the age window in which cancer screening intensifies.

Before starting tesamorelin, confirm the patient is current on age-appropriate cancer screening:

• Colonoscopy or equivalent (per USPSTF guidelines, recommended beginning at age 45) [9]
• Low-dose CT lung screening if applicable (20+ pack-year smoking history per USPSTF) [10]
• Mammography (for patients with breast tissue, every 1 to 2 years)
• Prostate-specific antigen discussion (shared decision-making for men aged 55 to 69)

IGF-1 elevation has been epidemiologically linked to colorectal and prostate malignancies in some observational studies [4]. While no causal relationship has been established with tesamorelin-induced IGF-1 increases, it is prudent to avoid initiating therapy in a patient who is overdue for screening.

During therapy, any new unexplained mass, weight loss, or change in bowel habits should prompt both cancer evaluation and temporary discontinuation of tesamorelin until malignancy is excluded.

Perimenopause, Andropause, and Hormonal Overlap

Adults aged 50 to 64 are frequently experiencing hormonal transitions. Women in perimenopause or early postmenopause have declining estrogen, which independently increases visceral fat deposition and cardiovascular risk. Men may have declining testosterone.

Tesamorelin does not directly affect sex hormone levels [5]. It does not convert to estrogen or testosterone. But the GH/IGF-1 axis interacts with gonadal hormones in ways that matter for symptom management.

A postmenopausal woman on hormone replacement therapy (HRT) who also starts tesamorelin is modifying two hormonal axes simultaneously. The North American Menopause Society recommends that HRT decisions be based on the balance of benefits and risks for the individual patient [11]. Adding tesamorelin does not change the HRT risk calculus directly, but the fluid retention and arthralgia side effects of tesamorelin can mimic estrogen-related side effects, complicating clinical assessment.

For men with concurrent testosterone replacement therapy (TRT), the combined anabolic effect of TRT plus GH-axis stimulation could theoretically accelerate prostate-related concerns, though this has not been demonstrated in trials. PSA monitoring at baseline and every 6 to 12 months is reasonable in men over 50 receiving both therapies.

Dr. Jordan Falutz, the lead investigator of the key tesamorelin trials, has noted: "The aging HIV population presents a unique intersection of metabolic, cardiovascular, and endocrine challenges. Tesamorelin addresses one piece of that puzzle, but it must be used within a comprehensive metabolic management framework" [1].

Hepatic and Renal Considerations

Tesamorelin has not been studied in patients with severe hepatic impairment (Child-Pugh C) [5]. Mild-to-moderate hepatic impairment did not meaningfully alter drug exposure in pharmacokinetic studies. For the 50-to-64 cohort, MASLD (metabolic-associated steatotic liver disease, formerly NAFLD) prevalence is high, especially among people with HIV-associated lipodystrophy.

One area of active research involves tesamorelin's potential benefit for hepatic steatosis. A study by Stanley et al. published in The Lancet HIV (N=61) found that tesamorelin reduced hepatic fat fraction by 37% over 12 months in people with HIV and NAFLD, compared with a 10% increase in the placebo group [12]. The 2023 Endocrine Society guidelines reference these findings as hypothesis-generating [2].

For renal function, tesamorelin is a peptide degraded by proteolysis, not by renal clearance of parent compound. No dose adjustment is recommended for renal impairment [5]. However, in patients aged 50 to 64 with estimated GFR between 30 and 60 mL/min, fluid retention side effects may be amplified. Monitor weight and edema more frequently.

When to Discontinue

The prescribing information recommends treatment reassessment if trunk fat has not decreased by at least 5% after 6 months of therapy [5]. In the older adult population, three additional discontinuation triggers deserve explicit protocols.

Stop tesamorelin if:

• IGF-1 exceeds 3 SDS above the age- and sex-adjusted mean on two consecutive draws.
• A new malignancy is diagnosed.
• Fasting glucose rises above 126 mg/dL or HbA1c exceeds 6.5% on two occasions despite diabetes management optimization.

After discontinuation, visceral fat reaccumulates within 3 to 6 months [1]. The CDC's guidelines on HIV-associated metabolic complications note that non-pharmacologic interventions (structured exercise, dietary modification) are first-line and should continue regardless of tesamorelin status [13].

For patients aged 50 to 64 who achieve sustained VAT reduction, an individualized discussion about continued therapy versus supervised discontinuation with imaging surveillance (CT or MRI for VAT quantification) every 6 months represents the standard of care at most academic HIV centers.

The Endocrine Society recommends: "Growth hormone releasing hormone analogs should be prescribed with ongoing reassessment of the risk-benefit ratio, particularly as patients age and accumulate additional comorbidities" [2]. For a 62-year-old with well-controlled HIV, stable VAT on tesamorelin, and a new diagnosis of atrial fibrillation, that reassessment may favor discontinuation. For a 52-year-old with progressive lipodystrophy despite lifestyle modification, continuation with close monitoring remains appropriate.

Baseline IGF-1 in a 55-year-old averages 30% lower than in a 35-year-old, so a post-treatment value that appears "normal" on a non-age-adjusted scale may actually represent clinically significant elevation [6].